EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Limited Diagnostic Performance of Cerebrospinal Fluid Glial Fibrillary Acidic Protein in Dementia

Pontus Erickson, Tobias Borgh Skillbäck, Silke Kern, Ingmar Skoog, Linus Jönsson, Ulf Andreasson, Kaj Blennow, Maria Eriksdotter, Henrik Zetterberg

Dementia and Geriatric Cognitive Disorders · 2026

DOI: 10.1159/000550601 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dementia and Geriatric Cognitive Disorders, 2026. Verfasst von Pontus Erickson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothe…. Hauptthemen laut MEDLINE: Glial Fibrillary Acidic Protein, Dementia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cerebrospinal fluid (CSF) glial fibrillary acidic protein (GFAP) is a neuroinflammatory marker reflecting reactive astrogliosis and is measured regularly in clinical practice. However, its diagnostic utility in differentiating dementia subtypes remains unclear. This study aimed to evaluate differences in CSF GFAP concentrations and its associations with markers of disease severity and amyloid pathology.

Methods

We conducted a retrospective cohort study using three datasets encompassing a broad range of dementia diagnoses. Included variables were CSF GFAP, β-amyloid 42 (Aβ42), the Aβ42/Aβ40 ratio, Mini-Mental State Examination (MMSE) scores, and time from sampling to death.

Results

A total of 1,345 individuals were included. In Parkinson’s disease dementia (PDD) and Lewy body dementia, GFAP levels were similar (p > 0.05). Lower levels were observed in PDD compared to early-onset Alzheimer’s disease (EAD), late-onset AD (LAD), and vascular dementia (VaD) (all p < 0.05); however, the discriminative performance was low-to-moderate: PDD versus LAD (AUROC = 0.74, CI = 0.64–0.84, p < 0.001), VaD (AUROC = 0.71, CI =0.61–0.81, p < 0.001) and EAD (AUROC = 0.59, CI = 0.47–0.71, p = 0.13). Associations were seen with MMSE in mixed AD and VaD (p = 0.027), but not in the other diagnostic categories. GFAP levels did not differ between subjects grouped according to Aβ42/Aβ40 status (p > 0.05).

Conclusion

CSF GFAP did not exhibit clinically relevant diagnostic or prognostic value in dementia. Further studies are needed to clarify its role in PDD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glial Fibrillary Acidic ProteinDementiaHumansMaleFemaleAmyloid beta-PeptidesAgedRetrospective StudiesBiomarkersDementia, VascularAlzheimer DiseaseAged, 80 and overPeptide FragmentsParkinson DiseaseLewy Body Disease

Stichwörter der Autor:innen

Alzheimer’s diseaseAβ42/40Glial fibrillary acidic proteinParkinson’s diseaseVascular dementia

Substanzen

Glial Fibrillary Acidic ProteinAmyloid beta-PeptidesBiomarkersGFAP protein, humanPeptide Fragmentsamyloid beta-protein (1-42)amyloid beta-protein (1-40)

Autor:innen und Institutionen

  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden, pontus.eriksson@gu.se.
  • Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden, pontus.eriksson@gu.se.
  • Neuropsychiatric Epidemiology, Section of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden, pontus.eriksson@gu.se.
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
  • Neuropsychiatric Epidemiology, Section of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
  • Region Västra Götaland, Sahlgrenska University Hospital, Department for Neuropsychiatry, Mölndal, Sweden.

Zitieren

APA

Erickson, P., Borgh Skillbäck, T., Kern, S., Skoog, I., Jönsson, L., Andreasson, U., Blennow, K., Eriksdotter, M., & Zetterberg, H. (2026). Limited Diagnostic Performance of Cerebrospinal Fluid Glial Fibrillary Acidic Protein in Dementia. Dementia and Geriatric Cognitive Disorders. https://doi.org/10.1159/000550601

Vancouver

Erickson P, Borgh Skillbäck T, Kern S, Skoog I, Jönsson L, Andreasson U, et al. Limited Diagnostic Performance of Cerebrospinal Fluid Glial Fibrillary Acidic Protein in Dementia. Dementia and Geriatric Cognitive Disorders. 2026. doi:10.1159/000550601

BibTeX
@article{Erickson2026,
  author = {Erickson, Pontus and Borgh Skillbäck, Tobias and Kern, Silke and Skoog, Ingmar and Jönsson, Linus and Andreasson, Ulf and Blennow, Kaj and Eriksdotter, Maria and Zetterberg, Henrik},
  title = {Limited Diagnostic Performance of Cerebrospinal Fluid Glial Fibrillary Acidic Protein in Dementia},
  journal = {Dementia and Geriatric Cognitive Disorders},
  year = {2026},
  doi = {10.1159/000550601}
}
Kostenlos starten →